Printed from Voxsanity (voxsanity.com.au) — NCT06607926 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Lung Cancer Trial, Not Yet Recruiting
NCT06607926
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 to 70 years (male or female).
- People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) at stage II to IIIB(N2), confirmed by scans and tissue testing, where surgery is considered a possible treatment option.
- People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
- People whose lung cancer does not have specific genetic changes known as EGFR and ALK mutations.
- People who are generally well enough to carry out normal daily activities with little to no restriction (as rated by a standard medical scale scored 0 or 1).
- People with a life expectancy of more than 6 months.
- People who have not previously received any treatment for their lung cancer, including surgery, chemotherapy, radiation, targeted therapy, or immunotherapy.
- People who have agreed to undergo surgery aimed at removing the cancer completely.
- People assessed by a chest surgeon as having no medical reasons that would prevent surgery.
- People whose blood test results show the immune system, kidneys, liver, blood clotting, thyroid, and heart enzyme levels are within acceptable ranges as required by the trial (confirm with trial site for specific values).
- Women who could become pregnant must agree to use contraception during the trial and for 6 months after it ends, must have a negative pregnancy test within 7 days before joining, and must not be breastfeeding.
- Men must agree to use contraception during the trial and for 6 months after it ends.
- People who fully understand the trial and voluntarily sign the consent form before any trial-related procedures begin.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had another cancer within the past 5 years, except for certain skin cancers or carcinoma in situ that were completely treated.
- People whose lung cancer tests positive for EGFR or ALK genetic mutations, or where the result of these tests is unknown.
- People currently taking part in another interventional clinical trial, or who have received another experimental treatment or device within the past 4 weeks.
- People who have previously received any treatment for lung cancer, including surgery, radiation, chemotherapy, or immunotherapy such as PD-1, PD-L1, or CTLA-4 inhibitors.
- People who have used certain anti-tumour traditional Chinese medicines or immune-boosting drugs (such as thymopeptides, interferons, or interleukins) within the 2 weeks before starting the trial, except when used locally for fluid around the lungs.
- People who have had an active autoimmune disease requiring ongoing systemic medical treatment within the past 2 years (hormone replacement therapies for certain gland conditions are not included in this restriction).
- People who have used systemic steroid medications or other immune-suppressing treatments within 7 days before starting the trial, except for low-dose steroids at or below the equivalent of 10 mg per day of prednisone, or steroids used in the nose, lungs, or skin only.
- People who have had an organ transplant (other than a cornea transplant) or a bone marrow/stem cell transplant from another person.
- People who are allergic to any ingredient in the study drug.
- People who have not fully recovered from side effects or complications of a previous medical procedure before starting the trial.
- People with a known history of HIV infection.
- People with untreated, active hepatitis B infection (people with hepatitis B may still be considered eligible under certain conditions — confirm with trial site).
- People with active hepatitis C infection, confirmed by positive antibody and detectable virus levels.
- People who have received a live vaccine within 30 days before starting the trial (note: injected inactivated flu vaccines are allowed, but people who have received a live nasal flu spray vaccine will be excluded).
- Women who are pregnant or breastfeeding.
- People with serious or uncontrolled health conditions, including but not limited to:
- Significant abnormal heart rhythm or electrical activity on a heart tracing, causing severe symptoms that are difficult to control.
- Unstable chest pain, heart failure, or moderate-to-severe chronic heart failure.
- A heart attack, stroke, or related blood clot or blockage event within the past 6 months.
- Blood pressure that is not controlled (above 140/90 mmHg).
- A history of lung inflammation not caused by infection that required steroid treatment within the past year, or currently active lung scarring/inflammation.
- Active tuberculosis.
- An active or uncontrolled infection requiring treatment.
- Active bowel inflammation, abdominal abscess, or bowel blockage.
- Liver disease such as cirrhosis, liver failure, or active hepatitis.
- Poorly controlled diabetes with fasting blood sugar above 10 mmol/L.
- High levels of protein in the urine, above specified limits (confirm with trial site).
- A mental health condition that would make it difficult to follow the trial requirements.
- Any other condition, treatment, or abnormal test result that the trial doctor believes would make participation unsafe or unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Yi Zhang, Xuanwu Hospital, Beijing
Phone: +86-010-83922345
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Xuanwu Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
30 June 2025
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Pathologic complete response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.